iqvia glp-1 prescriptions semaglutide tirzepatide q3 2024 Momentum is building for oral Wegovy. Data from shows 3,071 U.S. in its first four days on the market. Investors are watching closely to see New Demand in an Old

This casecontrol study shows increased risk of AIT with a polymorphism in the SELENOS gene

How Orforglipron Stacks Up Against Wegovy and Zepbound Wegovy (semaglutide 2.4 mg weekly) produced an average weight loss of 14.9% over 68 weeks in the STEP 1 trial

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

While formal lipedema trials are still underway, the mechanistic rationale and early clinical reports suggest tirzepatide may be the most promising pharmacological option for this underserved condition

It can be chopped apart to form other molecules including GLP-1